Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone.

Division of Developmental Medicine, University of Glasgow, Royal Hospital for Sick Children, Glasgow G3 8SJ, Scotland, UK.
Archives of Disease in Childhood (Impact Factor: 2.91). 10/2006; 91(10):808-13. DOI: 10.1136/adc.2005.087247
Source: PubMed

ABSTRACT Clinical adrenal insufficiency has been reported with doses of inhaled fluticasone proprionate (FP) > 400 microg/day, the maximum dose licensed for use in children with asthma. Following two cases of serious adrenal insufficiency (one fatal) attributed to FP, adrenal function was evaluated in children receiving FP outwith the licensed dose.
Children recorded as prescribed FP > or = 500 microg/day were invited to attend for assessment. Adrenal function was measured using the low dose Synacthen test (500 ng/1.73 m2 intravenously) and was categorised as: biochemically normal (peak cortisol response > 500 nmol/l); impaired (peak cortisol < or = 500 nmol/l); or flat (peak cortisol < or = 500 nmol/l with increment of < 200 nmol/l and basal morning cortisol < 200 nmol/l).
A total of 422 children had been receiving FP alone or in combination with salmeterol; 202 were not investigated (137 FP within license; 24 FP discontinued); 220 attended and 217 (age 2.6-19.3 years) were successfully tested. Of 194 receiving FP > or = 500 microg/day, six had flat responses, 82 impaired responses, 104 were normal, and in 2 the LDST was unsuccessful. Apart from the index child, the other five with flat responses were asymptomatic; a further child with impairment (peak cortisol 296 nmol/l) had encephalopathic symptoms with borderline hypoglycaemia during an intercurrent illness. The six with flat responses and the symptomatic child were all receiving FP doses of > or = 1000 microg/day.
Overall, flat adrenal responses in association with FP occurred in 2.8% of children tested, all receiving > or = 1000 microg/day, while impaired responses were seen in 39.6%. Children on above licence FP doses should have adrenal function monitoring as well as a written plan for emergency steroid replacement.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine serum cortisol responses to a simplified low dose short Synacthen test (LDSST) in children treated with inhaled corticosteroids (ICS) for asthma and to compare these to early morning salivary cortisol (EMSC) and cortisone (EMSCn) levels. EMSC and EMSCn samples were collected for three consecutive days. On day three Synacthen 500ng/1.73m(2) was administered intravenously. Samples were collected at 0, 15, 25, 35 minutes. 269 subjects (160 M: 109F), median (range) age 10.0 (5.1 - 15.2) years were studied. Peak cortisol in the LDSST was <500nmol/L in 101 subjects (37.5%) and <350nmol/L in 12 subjects (4.5%). Basal cortisol correlated with peak cortisol: r=0.55, (95% CI: 0.46, 0.63, p<0.0001). Time at which peak cortisol concentration was achieved was significantly related to the value of peak cortisol (p<0.0001), with higher cortisol peaks occurring later in the test and lower cortisol peaks occurring earlier. EMSC and EMSCn had no predictive value for the identification of patients with a peak cortisol <500nmol/L. EMSCn was superior to EMSC in identifying patients with a peak cortisol < 350nmol/L: a minimum EMSCn cut-off value of 12.5 nmol/L gave a negative predictive value of 99.2% and positive predictive value of 30.1%. Our data illustrate that basal measures of cortisol are likely to be of value in screening populations for patients at greatest risk of adrenal crisis. EMSCn shows promise as a screening tool for the identification of patients with severe adrenal insufficiency. This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 07/2013; · 3.35 Impact Factor
  • Source
    European Journal of Internal Medicine 10/2014; 25(8):781–783. · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Adrenal insufficiency (AI) is a potentially life-threatening condition. It is known that high doses of inhaled corticosteroids (ICS) can induce systemic adverse effects. Currently, there are no data on the prevalence of AI associated with the use of ICS. This study aimed to investigate the prevalence and clinical presentation of AI (associated or not associated with exogenous Cushing’s syndrome) in patients who were prescribed ICS by French physicians during the period 2000–5. Methods: All metropolitan French paediatricians, endocrinologists, pulmonologists and intensive care physicians (n = 11 783) were mailed questionnaires requesting information regarding cases of AI associated or not associated with exogenous Cushing’s syndrome between 2000 and 2005. Data collected included patient demographics, oral corticosteroid or ICS used during the year preceding the diagnosis of AI, underlying condition(s), concomitant treatment(s), presenting clinical signs and symptoms, results of laboratory investigations and outcome. The French pharmacovigilance database was screened for spontaneous reports to determine the frequency of AI associated with the use of ICS, using the capturerecapture method. Results: Forty-six cases of AI were identified. Twenty-three cases presented with clinical symptoms of AI alone and 23 with exogenous Cushing’s syndrome. ICS prescribed were fluticasone propionate (n = 24), budesonide (n = 12) and beclometasone dipropionate (n = 5). In 82% (n = 32) of cases for which data were available, ICS were prescribed at high doses. A potential drug interaction was found in 12 cases. Thirteen cases of AI were identified in the French pharmacovigilance database, one of which was common with the questionnaire survey. The capture-recapture method provided an estimation of 598 (95% CI 551, 648) cases of AI associated with the use of ICS for the 2000–5 period in France. Conclusion: The results of this study confirm the occurrence of adrenal insufficiency in patients treated with ICS. Although the prevalence of ICS-induced AI reported in this study is low, the likelihood of under-diagnosis underlines the need to consider this risk in patients when prescribing these drugs.
    Drug Safety 01/2008; 31(9). · 2.62 Impact Factor

Full-text (2 Sources)

Available from
Jun 6, 2014